US EditionNICE issues final guidance endorsing Pharming’s APDS therapy
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
NICE issues final guidance endorsing Pharming’s APDS therapy
This recommendation facilitates treating the activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 years and above. The oral therapy is now accessible and funded in The post NICE issues final guidance endorsing Pharming’s APDS therapy appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
